The U.S. Market for Pet Medications: Prescription and Over-the-Counter Remedies as Consumer Products
Special offer: now 20% off original price of $3,300
At the center of robust global animal health product growth, the U.S. market for pet medications is going gangbusters, with continued double-digit sales gains predicted for the foreseeable future as all of the world’s largest pharmaceutical companies move full-force into the segment, adapting human technologies and developing pet-specific ones. Also driving market growth are the aging pet population and rising rates of pet overweight/obesity, spurring the need for new product types. Although antiparasitics (flea/tick products and heartworm remedies) remain at the core of the market—Merial’s Frontline (fipronil) achieved “blockbuster” billion-dollar status in 2007, and Bayer’s Advantage is also going strong—companies are now branching out with new consumer-targeted pet medications, such as Pfizer’s Slentrol for weight-loss and Eli Lilly’s Reconcile for separation anxiety.
Bringing in broad pet market perspective based on more than a dozen other pet market reports, along with a unique “cross-market” focus examining trends in both the veterinary (pharmaceutical) and retail (OTC) sectors, this all-new report from Packaged Facts analyzes the market for medications for dogs and cats, with a particular focus on products marketed directly to consumers. Areas covered include parasite prevention and control (flea, tick, heartworm, etc.), pain management (focusing on non-steroidal anti-inflammatory drugs), mood disorders, overweight/obesity, cognitive dysfunction and oral care. Top U.S. marketers profiled include all of the largest pharmaceutical companies (Pfizer, Intervet-Schering, Bayer, Fort Dodge, Novartis, etc.) as well as the top marketers of retail pet health lines (Central Garden & Pet, Hartz, Sergeant’s).
Other high-interest areas examined in this report—all from the perspective of their potential impact on future market performance—include product diversion outside the veterinary channel, growth of online retailing via outfits including PetMed Express, the effects of the 2008 economic crisis, and the possibility of ethical brands’ moving officially into retail channels. Retail sales are quantified and projected forward through 2012, while the retail performance of pet medication marketers and brands is evaluated using Information Resources, Inc. InfoScan Review data. In addition, uniquely cross-tabulated consumer survey data from Simmons Market Research Bureau provides penetrating insight into pet medication consumer usage rates, demographics and psychographics.